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Available online xxxxObjectives: The aim of this study was to evaluate the efficacy and safety of the combination Gemcitabine (Gem)
plus nab-Paclitaxel (NabP) (Gem/NabP), followed by maintenance Gem in older adults with locally advanced or
metastatic pancreatic cancer (PC).
Materials and methods: In this prospective observational study, the induction chemotherapy consisted of NabP
125 mg/m2 followed by Gem 1000 mg/m2 on days 1, 8, and 15 of a 4-week cycle. After a maximum of 3 cycles,
patients without evidence of progressive disease (PD) were administered Gem 1000 mg/m2 weekly for 3 of
4 weeks as maintenance therapy until documentation of PD or unacceptable toxicity. The primary endpoint
was six-month disease-control rate (DCR).
Results: Overall, 36 patients N70 years withmetastatic or locally advanced PCwere enrolled at participating Institu-
tions. After completion of Gem/NabP, 18 (50%) patients achieved partial response, 13 (36%) had stable disease, and5
(14%) had PD. Thirty-one patients (86%) received Gemmonotherapy as maintenance treatment for a median of
3 cycles (range, 2–9 cycles). Six-month DCR was 61% (95% CI, 45–77), median PFS was 6.4 months (95% CI,
5.4–8.3), and median OS was 13.4 months (95% CI, 11.1–16.7). During Gem/NabP regimen, the most common
grade 3 toxicity included neutropenia (22%), anemia (19%) and thrombocytopenia (8%). Grade 3 neuropathy was
not observed. During Gemmaintenance therapy, grade 3 hematological toxicity was described in 6 patients (19%).
Conclusion:Gem/NabP followed bymaintenance Gem appears to be safe and effective for older patientswith locally
advanced or metastatic PC.






The incidence of pancreatic cancer (PC) in the United States is
steadily rising and 55,440 new cases were expected for 2018 [1]. Most
patients present with locally advanced unresectable or metastatic
disease and the 5-year survival rate is approximately 3% mainly due to
the early metastatic dissemination [1,2].
Gemcitabine (Gem) has been the standard first-line treatment
for patients with advanced PC until 2011 when the chemotherapy
combination fluorouracil + irinotecan + oxaliplatin (FOLFIRINOX)
was shown to increase median overall survival (OS) compared withpartment of Medicine, Surgery
0 Siena, Italy.
li).
re, G. Pesola, et al., Gemcita
l, https://doi.org/10.1016/j.jgoGemalone (11.0 vs.. 6.8months; hazard ratio [HR], 0.57; 95% confidence
interval [CI], 0.45–0.73; P b .001) [3]. Despite these positive results, a
higher rate of severe adverse events have been observedwith this com-
bination regimen and thus particular caution should be exercised when
using it for older subjects [3].
In 2013, the international phase III randomized trial MPACT demon-
strated that the combination gemcitabine plus nab-paclitaxel (Gem/
NabP) compared to Gem monotherapy for patients with metastatic PC
and a Karnofsky performance status (KPS) ≥ 70 prolongs median OS
(8.5 vs. 6.7months; HR=0.72; 95% CI, 0.62–0.83; P b .001),median pro-
gression free survival (PFS) (5.5 vs. 3.7 months; HR = 0.69; 95% CI,
0.58–0.82; P b .001), and objective response rate (ORR) (23% vs. 7%;
P b .001) [4]. The incidence of the most common grade ≥ 3
treatment-related adverse events (neutropenia, fatigue, and peripheral
neuropathy) was higher in the Gem/NabP group than in the Gem alonebine plus nab-paclitaxel followed by maintenance treatment with
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reported in 17% vs 1% of the patients in the two groups. Of note, most pa-
tients receiving Gem/NabP were b65 years and had a good performance
status (PS), hence safety and efficacy data for older and vulnerable pa-
tients are limited. Older adults with cancer often have comorbidities
which complicate the administration of aggressive treatments. In clinical
practice, Gem monotherapy or best supportive care are often recom-
mended for patients N75–80 years with advanced PC [5]. On the other
hand, older patients with good PS and considered fit according to com-
prehensive geriatric assessment (CGA) might benefit by the administra-
tion of a multidrug treatment. In colorectal cancer, stop and go or
intermittent chemotherapy were shown to be valid alternative treat-
ment schedules to reduce neuropathy [6–8]. However, to the best of
our knowledge, current literature lacks data surrounding the use of sim-
ilar treatment strategies with Gem/NabP in advanced PC. Given the rela-
tively good activity and toxicity profile of Gem, the administration of
Gem/NabP for a limited number of cycles followed by Gem as mainte-
nance could minimize the severity of adverse events in the older adult.
The present study sought to prospectively evaluate the clinical effi-
cacy and tolerability of induction chemotherapy with Gem/NabP
followed by Gem as maintenance treatment for non-frail patients
N70 years with advanced PC.
2. Patients and methods
2.1. Eligibility criteria
This multi-institution prospective observational study included pa-
tients N70 years with locally advanced ormetastatic histologically or cy-
tologically proven pancreatic cancer (PC), who had not previously
received chemotherapy for this stage of disease. Any adjuvant treat-
ment completed at least 12 months before inclusion was allowed. All
patients had to present at study entry with an Eastern Cooperative On-
cology Group (ECOG) PS of ≤2 and adequate hematological (leukocytes
≥3000/mm3; hemoglobin ≥10 g/dL, platelets ≥100,000/mm3), renal
(serum creatinine ≤2.0 mg/dL) and hepatic function (serum bilirubin
≤2.0 mg/dL). The exclusion criteria were a congestive heart failure, re-
cent myocardial infarction, or co-existence of any other malignant dis-
ease except basal cell carcinoma of the skin. Patients b75 years with
ECOG PS = 0 were also excluded as considered candidate to receive
conventional Gem/NabP or FOLFIRINOX chemotherapy.
Patients with high bilirubin and/or high aspartate and alanine ami-
notransferase levels were admitted provided that stenting or bypass
surgery with the aim of stabilizing liver function were performed prior
to starting chemotherapy. In this respect, total bilirubin, aspartate, or al-
anine aminotransferase levels N3 x the upper normal limit before
starting treatment were also exclusion criteria. A baseline geriatric as-
sessment including activities daily living (ADL), instrumental activities
of daily living (IADL), and the Charlson score for comorbidities [9] was
carried out, and patients were consequently classified as fit, vulnerable,
and frail. Specifically, subjects with ADL limitations and more than two
comorbidities were classified as frail and were excluded from the study
[10]. All patients signed the informed consent to treatment. Patients
were recruited fromfive participating institutions including ourMedical
Oncology Unit which designed and coordinated the study (Mantova,
northern Italy; Siena, Grosseto, Rome, center Italy; Lecce, south Italy).
2.2. Treatment plan
Induction chemotherapy consisted of Nab-Paclitaxel 125 mg/m2
followed by Gem 1000 mg/m2 on days 1, 8, and 15, every 4 weeks
(1 cycle) for a maximum of 3 cycles. For patients N80 years, the number
of planned cycles was two. Full-dose Gem and NabP was administered
only to patients ≤80 years and fit. Chemotherapy dose was reduced by
20–30% for vulnerable patients and subjects N80 years, to minimize
the occurrence of treatment-related adverse events. MaintenancePlease cite this article as: R. Petrioli, P. Torre, G. Pesola, et al., Gemcita
gemcitabine alone as first-li..., J Geriatr Oncol, https://doi.org/10.1016/j.jgotreatment consisted of weekly Gem 1000 mg/m2 (800 mg/m2 for vul-
nerable or N 80 years patients) for 3 of 4 weeks and was continued
until documentation of progressive disease or unacceptable toxicity.
Cycles were administered if serum white blood cells count was
N3000/mm3, granulocytes N1500/mm3, and platelets N100,000/mm3.
2.3. Patient evaluation
All patients underwent a baseline ECG and their left ventricular ejec-
tion fraction (LVEF) was measured by means of a multiple gated acqui-
sition scan or echocardiography. A complete physical examination,
monitoring of symptoms and toxic effects, assessment of renal function,
CEA and CA 19–9markers, and a complete blood count were performed
on patients at the start of every chemotherapy cycle. The disease was
re-assessed after completion of three cycles of Gem/NabP, and then
thereafter at 3-month intervals until there was evidence of disease pro-
gression (PD). Objective tumor responsewas evaluated according to Re-
sponse Evaluation Criteria in Solid Tumors (RECIST criteria, version 1.1).
2.4. Toxicity
The common toxicity criteria of the National Cancer Institute Com-
mon Terminology Criteria for Adverse Events (NCI-CTCAE; version
4.02) were used to assess toxicity. Treatment was delayed if, on the
planned day of therapy, the neutrophil count was b1500/mm3, or the
platelet count was b100,000/mm3, or the patient had persistent
diarrhea or stomatitis Ngrade 1. Any patient who required N3 weeks to
recover from side effects was excluded from the study. A 25% dose
reduction of the chemotherapy drugs was applied for subsequent
courses in case of grade 4 hematologic or any ≥grade 3 organ toxicity.
2.5. Statistical considerations
The primary endpoint of the study was 6-months disease-control
rate (DCR) defined as the proportion of patients who obtained stable
disease (SD) or partial (PR) or complete response (CR) within
6 months after starting induction treatment. Most studies investigating
Gem monotherapy for older adults with advanced PC report that ap-
proximately 20–25% of patients are still progression-free at 6 months
after treatment onset [5,11]. The hypothesis of the current study was
that, using Gem/NabP as induction chemotherapy and Gem as mainte-
nance treatment, at least 40% of patients would be progression-free
after 6 months from chemotherapy initiation. It was calculated that at
least 33 patients should be enrolled to yield a 80% probability to cor-
rectly select the therapy when it is superior by absolute difference of
20% in 6-months DCR (Simon's minimax design) [12]. Safety, PFS (mea-
sured as the time from the first chemotherapy to PD or death from any
cause or last follow-up visit, whichever came first), and OS (assessed
from treatment start to death or last follow-up visit, whichever came
first) and ORR (as the rate of patients achieving PR or CR) were the
secondary endpoints. Kaplan-Meier method was utilized to assess the
distributions of PFS and OS, including median time-to-event and its
95% CI. Statistical analyses were performed by MEDCALC software.
3. Results
3.1. Patient characteristics
Between May 2014 and June 2018, 36 patients with advanced or
metastatic PC were treated with Gem/NabP and maintenance Gem at
participating institutions. Baseline demographic and clinical character-
istics of patients are described in Table 1. Median age was 77 years
(range, 71–86 years) and 6 of 36 patients (17%) were aged over
80 years. Most patients (33 of 36; 92%) had an ECOG PS of 0 or 1 and
21 of 36 patients (58%) were classified as fit. Six patients (17%) had un-
dergone surgical resection of the primary tumor with curative intentbine plus nab-paclitaxel followed by maintenance treatment with
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Table 1
Main patient characteristics at baseline.
Variable All patients (N = 36)
















Median, U/mL (range) 851.7 (2.6–21,360.4)
Geriatric assessment, No (%)
Fit 21 (58)
Vulnerable 15 (42)
Charlson Comorbidity Index, No (%)








Lymph node 27 (75)
Lung 8 (22)
Peritoneal 11 (31)
Number of metastatic sites
N1 25 (69)




Objective response rate, N (%) 18 (50)
Complete response 0
Partial response 18 (50)
Stable disease 13 (36)
Progressive disease 5 (14)
6-month disease control rate, % (95% CI) 61 (45–77)
Median progression free survival, months (95% CI) 6.4 (5.4–8.3)
Median overall survival, months (95% CI) 13.4 (11.1–16.7)
Median follow-up, months (range) 15.3 (5–42)
3R. Petrioli et al. / Journal of Geriatric Oncology xxx (2019) xxxand were offered to enter the study once the metastatic disease was ra-
diologically proven. Twenty-eight of 36 patients (78%) presented at diag-
nosiswith distant disease and twenty-one (58%) had livermetastases. At
baseline, the majority of patients (22 of 36; 61%) had N1 comorbidity
(Table 2) and the most frequent were cardiovascular diseases (16 of
36; 44%). Polypharmacy (5+) was documented in 38.8% of patients.
ADL and instrumental ADL dependencies were reported in 27.7% and
38.8% of patients, respectively. The most affected basic ADLs were walk-
ing, transfers and eating. Concerning IADLs, householdmanagementwas
most commonly affected.Weight loss was described in 58.3% of patients,
and the mean value of baseline body mass index was 25.4 + 5 standard
deviation. Cognitive impairment was reported in 5 patients (13.8%).3.2. Efficacy
All 36 patients completed the planned chemotherapy and were
evaluable for response and toxicity. A total of 102 cycles of Gem/NabP
(median, 3 cycles; range 2–3) was administered. The median relativeTable 2
Patient comorbidities.
Comorbidities Number of patients (%)
Cardiovascular 17 (47)
Hypertension 14 (39)
Coronary artery disease 6 (17)
Arrhythmia 4 (11)




N1 comorbidity 22 (61)
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N80 years received two cycles of induction chemotherapy. The starting
dose of NabP and GEM was 125 mg/m2 and 1000 mg/m2, respectively,
in 19fit patients ≤80 years and100mg/m2 and 800mg/m2, respectively,
in 15 vulnerable patients and in 2 fit patients N80 years. The ORR was
50%. No patient achieved CR while 18 subjects (50%) achieved PR and
13 (36%) SD, as best response to therapy after initial Gem/NabP
(Table 3). The 31 patients (86%) who achieved PR or SD after induction
treatment received maintenance chemotherapy with Gem for a median
of 3 cycles (range, 2–9 cycles). The ORR for Gemmaintenance treatment
was 6%. Twenty-nine patients discontinued maintenance chemotherapy
because of PD and for 8 of these, fit and b 80 years, NabP was
reintroduced. One patient was lost to follow-up after seven months
from the onset of induction chemotherapy while two patients remain
on maintenance treatment at the time of this writing. The 6-months
DCR was 61% (95% CI, 45–77) and median PFS was 6.4 months (95% CI,
5.4–8.3). After amedian follow-up of 15.3months (range, 5–42months),
a total of 31 patients were deceased and median OS was 13.4 months
(95% CI 11.1–16.7). Distributions of PFS and OS for the 36 enrolled
patients are described in Fig. 1. In the locally advanced and metastatic
subgroups, PFS was 8.3 months and 6.1 months and OS 17.3 and
11.2 months, respectively. A relevant CA 19–9 response, defined as a
decrease N50% from an elevated baseline value, was observed in 27
(75%) patients after induction chemotherapy. Finally, 16 patients (44%)
received an irinotecan-based chemotherapy as second-line treatment
and 9 (25%) patients received capecitabine alone as third-line therapy.
3.3. Toxicity
Adverse events rates during Gem/NabP induction regimen are sum-
marized in Table 4. Grade 3 toxicity included neutropenia (22%), anemiaFig. 1.Kaplan-Meier estimates of PFS (\\) andOS (—) fromGem/NabP start. Abbreviations:
Gem/NabP: gemcitabine plus nab-paclitaxel; PFS: progression-free survival; OS: overall
survival.
bine plus nab-paclitaxel followed by maintenance treatment with
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Table 4
Adverse events during gemcitabine plus nab-paclitaxel induction treatment.
Grade 2 Grade 3 Grade 4
Hematological
Neutropenia 5 (14) 8 (22) 2 (5)
Anemia 13 (36) 7(19) 0
Trombocytopenia 6 (17) 3 (8) 0
Non-hematological
Nausea 6 (17) 0 0
Vomiting 4 (11) 0 0
Fatigue 8 (22) 1 (3) 0
Stomatitis 3 (8) 0 0
Sensory neuropathy 6 (17) 0 0
Diarrhea 3 (8) 2 (5) 0
Constipation 4 (11) 2 (5) 0
Note: Data are expressed as numbers (%) except where otherwise noted.
4 R. Petrioli et al. / Journal of Geriatric Oncology xxx (2019) xxx(19%), thrombocytopenia (8%). Sensory neuropathy, related to the use
of NabP, never reached grade 3. Due to side effects, a total of 12 Gem/
NabP administrations were delayed and a dose reduction of GEM/
NabP was necessary for 9 (25%) patients. Maintenance treatment was
associated with mild toxicity and only 6 patients (19%) experienced
grade 3 hematologic toxicity (Table 5). Six patients (17%) needed a
dose reduction of Gem monotherapy.
4. Discussion
The combination treatment Gem/NabP improved median OS, PFS,
and ORR compared to Gem alone for patients with metastatic PC in a
large randomized phase 3 trial; however, data on the efficacy and safety
of this doublet chemotherapy for older adultswith advanced PC are cur-
rently limited and, also considering that older patients frequently pres-
ent with comorbidities, mono-chemotherapy or best supportive care
are generally preferred in routine clinical care. A reasonable approach
for non-frail older adults with advanced PC could be an initial short-
term combination chemotherapy followed by Gem alone as mainte-
nance treatment. In this respect, to the best of our knowledge, this is
the first study suggesting the feasibility and activity of Gem/NabP for
3 cycles followed by Gem monotherapy as maintenance treatment for
patients over 70 years with locally advanced or metastatic PC. Despite
the limitations of a small study, the 61% 6-month DCR, 6.4 months me-
dian PFS, and13.4monthsmedianOS achieved in our analysis are in line
with the results commonly observed with more active combination
chemotherapies in younger populations [3,4,13]. In this respect, a recent
multicenter real-world study of 75 patients treated with Gem/NabP for
advanced PC reported similar or slightly shorter median PFS (5.2 vs.
6.4 months, respectively) and OS (10.9 vs. 13.4 months, respectively)
than those observed in the current study [14]. Of note, although the
above-mentioned retrospective experience confirmed the effectiveness
and safety of first-line Gem/NabP in a real world setting, grade 3–4 he-
matologic toxicity occurred frequently and dose reductions were
needed in a higher proportion of patients compared to our report
(80% vs. 25%). A recent phase III study analysing NabP plus the oral
fluoropyrimidine derivative S-1 followed by S-1 as maintenanceTable 5
Adverse events during gemcitabine maintenance treatment.
Grade 2 Grade 3
Neutropenia 12 (39) 4 (13)
Anemia 21 (68) 6 (19)
Trombocytopenia 15 (48) 6 (19)
Nausea/vomiting 2 (6) 0
Fatigue 4 (13) 1 (3)
Diarrhea 1 (3) 0
Rash 1 (3) 0
Note: Data are expressed as numbers (%) except where otherwise noted.
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(53.1%), median PFS (6.2 months), and OS (13.6 months) similar to
our analysis [15]. However, the median age of the study population
was much younger (53 vs. 77 years) compared to our report and only
6 patients were over 80 years old. Conversely, a retrospectivemulticen-
ter study of unselected PC patients treated with Gem/NabP described
lower median PFS (5.0 months) and OS (7.2 months) compared with
our findings. However, it should be noted that this study population
had poorer ECOG PS and the median RDI was only 66.7% [16]. In fact,
the authors reported Gem/NabP dose reductions or discontinuations
for 65% and 17% of patients, respectively, due to toxicity. A point to con-
sider is that the current prospective observational study included a few
patients (8 of 36; 22%) with locally advanced unresectable tumor. This
stage of PC is usually associated with a better prognosis compared to
metastatic disease [17]. As a matter of fact, despite the subgroups
being quite small, a considerably higher median OS could be observed
for patients with advanced PC vs. distant disease (18.3 vs.
11.2months, respectively). Other authors recently reported similar out-
comes for locally advanced ormetastatic PC patients cohort treatedwith
Gem/NabP or FOLFIRINOX [18].
Interestingly, alternative treatment strategies were recently
experimented to minimize Gem/NabP adverse events. A “stop and go”
approach (named OPTINAB), consisting of suspending NabP at first oc-
currence of grade 3 neuropathy and re-instituting it at time of biochem-
ical or radiological progression, was recently applied in a small
retrospective clinical study including advanced PC patients receiving
Gem/NabP. The OPTINAB strategy was well tolerated and achieved an
OS (11.7months; range, 9.5–17months) comparable to that of our anal-
ysis which, however, included older patients andmostly (78%) at a later
stage of disease [19]. Furthermore, our results compare well with those
recently reported with a less intensive regimen of Gem/NabP such as a
biweekly schedule (about 5 months median PFS and 10 months OS)
[20,21]. However, although older adults participated in the aforemen-
tioned studies, the median age of enrolled patients was at most
67 years, while the median age was 77 years in our population study.
Despite the advanced median age and considerable rate of patients
with at least 2 comorbidities of our study population, treatment was
well tolerated and therewere no unexpected toxic effects. The treatment
strategy we proposed seemed to allow for avoiding the cumulative tox-
icities of NabP and prolong duration of chemotherapywith GEMalone as
maintenance treatment. Of note, in several cases the starting dose of
Gem and NabP was lower than the conventional starting dose of
1000 mg/m2 and 125 mg/m2, respectively. However, such dose reduc-
tions were due to the high proportions of subjects classified as non-fit
(42%) or presenting with N1 concomitant disease (61%). This could also
partly explain the relatively low rate of grade 3–4 neutropenia (22%)
and grade 2 only nausea and vomiting observed in our study during ini-
tial Gem/NabP regimen. A similar or also higher grade 3–4 hematologic
toxicity (up to 40%) compared with results observed in our population
study was reported with the modified biweekly Gem/NabP regimen
[20,21]. Nevertheless, despite the biweekly Gem/NabP regimen
appearing to be effective with an acceptable toxicity profile in advanced
PC patients, its potential benefits in older adults in comparison with the
standard weekly regimen needs to be confirmed by prospective studies.
In addition, it should be noted that sensory neuropathy never
reached grade 3. This safety profile is better than usually reported
with conventional Gem/NabP for younger patients and could be mainly
the result of the shorter exposure to NabP achieved with our treatment
schedule, the accurate selection of non-frail subjects, and the Gem and
NabP starting dose reductions. In this regard, despite still not existing
consensus over the definition of frailty status, we deem that an age
b 85 years, b3 concomitant comorbidities, the ability to perform the
daily living activities, and no cognitive impairment are the elements
which best define a non-frail patient.
Abaseline geriatric evaluation is useful todecide ifmonochemotherapy
or amore aggressive treatmentwill be used in older adults with advancedbine plus nab-paclitaxel followed by maintenance treatment with
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worldwide evaluating a CGA-driven treatment allocation to personalize
cancer therapy for older adults with metastatic pancreatic ductal adeno-
carcinoma [22].
The one-arm design, relatively small population, and long study
duration (4 years) are potential limits that prevent us from drawing
general conclusions from our report. Although carefulmonitoring of po-
tential side effects in older patients is recommended, the current study
suggests that induction chemotherapy with Gem/NabP followed by
maintenance treatment with Gem monotherapy might be safely pro-
posed as first-line treatment for non-frail patients aged N70 years with
advanced PC. Despite larger randomized trials are required to confirm
our results, the present findings could aid treatment decision making
for non-frail older adults with locally advanced or metastatic PC.
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